ES8702950A1 - Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos - Google Patents

Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos

Info

Publication number
ES8702950A1
ES8702950A1 ES543391A ES543391A ES8702950A1 ES 8702950 A1 ES8702950 A1 ES 8702950A1 ES 543391 A ES543391 A ES 543391A ES 543391 A ES543391 A ES 543391A ES 8702950 A1 ES8702950 A1 ES 8702950A1
Authority
ES
Spain
Prior art keywords
monoclonal antibodies
processes
human mif
cell lines
hybridoma cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES543391A
Other languages
English (en)
Other versions
ES543391A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES543391A0 publication Critical patent/ES543391A0/es
Publication of ES8702950A1 publication Critical patent/ES8702950A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

METODO PARA LA PURIFICACION DE FACTORES HUMANOS DE INHIBICION DE LA MIGRACION DE MACROFAGOS HUMANOS Y DE SUS PROTEINAS. COMPRENDE LA PREPARACION DE UNA DISOLUCION QUE CONTIENE UN FACTOR DE INHIBICION DE LA MIGRACION DE MACROFAGOS HUMANOS, A PARTIR DE CULTIVOS CELULARES DE CELULAS MONONUCLEARES ESTIMULADAS Y CULTIVADAS CON CONCAVALINA A; ULTRACENTRIFUGACION Y CONCENTRACION DE LA MISMA; PUESTA EN CONTACTO DE LA DISOLUCION CONCENTRADA CON SOPORTES QUE CONTIENEN ANTICUERPOS MONOCLONALES ESPECIFICOS RESPECTO DE DICHO FACTOR; SEPARACION DE LAS PROTEINAS Y DE LAS DEMAS SUSTANCIAS NO LIGADAS; Y SEPARACION DEL FACTOR LIGADO A LOS ANTICUERPOS, MEDIANTE DISOCIACION SELECTIVA. ESTOS FACTORES TIENEN APLICACIONES FARMACOLOGICAS PARA LA DIAGNOSIS Y EL TRATAMIENTO DE ENFERMEDADES INMUNO-REGULADORAS E INFLAMATORIAS CRONICAS.
ES543391A 1984-05-24 1985-05-22 Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos Expired ES8702950A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH255784 1984-05-24
CH378684 1984-08-07
CH544684 1984-11-14
CH51285 1985-02-05

Publications (2)

Publication Number Publication Date
ES543391A0 ES543391A0 (es) 1987-01-16
ES8702950A1 true ES8702950A1 (es) 1987-01-16

Family

ID=27427909

Family Applications (3)

Application Number Title Priority Date Filing Date
ES543391A Expired ES8702950A1 (es) 1984-05-24 1985-05-22 Procedimiento para la obtencion purificada de un factor de inhibicion de la emigracion de macrofagos humanos
ES557072A Expired ES8801850A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de lineas celulares de hibridoma
ES557071A Expired ES8801852A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de anticuerpos monoclonales contra el factor de inhibicion de emigracion de macrofagos humanos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES557072A Expired ES8801850A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de lineas celulares de hibridoma
ES557071A Expired ES8801852A1 (es) 1984-05-24 1986-09-16 Procedimiento para la obtencion de anticuerpos monoclonales contra el factor de inhibicion de emigracion de macrofagos humanos.

Country Status (8)

Country Link
EP (1) EP0162812B1 (es)
JP (3) JPH0672158B2 (es)
AT (1) ATE93869T1 (es)
DE (1) DE3587553D1 (es)
DK (1) DK171646B1 (es)
ES (3) ES8702950A1 (es)
IE (1) IE60450B1 (es)
IL (1) IL75280A0 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623850D0 (en) * 1986-10-03 1986-11-05 Ciba Geigy Ag Lymphokine related peptide
DE3789413T2 (de) * 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
EP0463037A1 (en) * 1989-03-17 1992-01-02 Genetics Institute, Inc. Human macrophage migration inhibitory factor
GB8915414D0 (en) * 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
US5107906A (en) * 1989-10-02 1992-04-28 Swenson Paul F System for fast-filling compressed natural gas powered vehicles
US5149544A (en) * 1989-11-13 1992-09-22 Research Corporation Technologies, Inc. Method of inhibiting progenitor cell proliferation
EP0702566B1 (en) * 1993-05-17 2010-07-21 Cytokine Pharmasciences, Inc Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
US20030235584A1 (en) 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies
DE10121255A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060229314A1 (en) 2005-03-24 2006-10-12 Jagadish Sircar Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
AU2012320597C1 (en) * 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2755363C3 (de) * 1977-12-12 1983-12-01 R & Z Biologicals Beteiligungsgesellschaft mbH, 4050 Mönchengladbach Testverfahren zur Diagnose von Malignomen
US4299814A (en) * 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
DD230876A1 (de) * 1983-05-09 1985-12-11 Akad Wissenschaften Ddr Verfahren zur gewinnung monoklonaler antikoerper gegen human-mif

Also Published As

Publication number Publication date
IL75280A0 (en) 1985-09-29
ES557072A0 (es) 1987-08-01
JPH0770192A (ja) 1995-03-14
IE851295L (en) 1985-11-24
JPH0780915B2 (ja) 1995-08-30
EP0162812A3 (en) 1988-04-20
JPH0672158B2 (ja) 1994-09-14
ES8801852A1 (es) 1988-02-16
JPH06217789A (ja) 1994-08-09
DK229985D0 (da) 1985-05-23
DE3587553D1 (de) 1993-10-07
EP0162812B1 (de) 1993-09-01
DK171646B1 (da) 1997-03-03
JPS60248617A (ja) 1985-12-09
ES543391A0 (es) 1987-01-16
ES557071A0 (es) 1988-02-16
DK229985A (da) 1985-11-25
ATE93869T1 (de) 1993-09-15
JPH07108915B2 (ja) 1995-11-22
IE60450B1 (en) 1994-07-13
ES8801850A1 (es) 1987-08-01
EP0162812A2 (de) 1985-11-27

Similar Documents

Publication Publication Date Title
ES8801850A1 (es) Procedimiento para la obtencion de lineas celulares de hibridoma
AU4088685A (en) Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
Yoshizaki et al. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors.
IE861543L (en) IgE-BF
Reinhold et al. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production
ATE132197T1 (de) Monoklonale antikörper
DE69531345D1 (de) Rekombinant pgp3, verfahren zu dessen herstellung, und dessen verwendung in der diagnose und therapie
Van Damme et al. Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8
IL71017A (en) Hybrid cell lines,monoclonal antibodies prepared thereby and their use in the purification,diagnosis and detection of human interferon of type alpha
EP0265384A3 (en) Monoclonal antibodies to a colony stimulating factor
AU608216B2 (en) Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
Kehrl et al. The direct effects of interleukin 1, interleukin 2, Interferon-α, Interferon-γ, B-cell growth factor, and a B-cell differentiation factor on resting and activated human B cells
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
Horton et al. Partial purification of a bone-resorbing factor elaborated from human allogeneic cultures
Meager et al. A two-site sandwich immunoradiometric assay of human lymphotoxin with monoclonal antibodies and its applications
Shimokawa et al. Lymphocyte chemotaxis in inflammation. VII. Isolation and purification of chemotactic factors for T lymphocytes from PPD-induced delayed hypersensitivity skin reaction site in the guinea-pig.
Knudsen et al. Elevated intracellular cAMP levels inhibit interleukin-1 production by the tumour cell line U937
Kishimoto et al. Polymorphism of submandibular-sublingual salivary proteins which promote adhesion of Streptococcus mutans serotype-c strains to hydroxyapatite
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
EP0238971A3 (en) Antibodies directed to a lymphokine
Kull Jr et al. Macrophage cytotoxin: Sources and mechanism
Booth et al. Interleukin-2 is required for the induction of erythrocyte-specific antibody responses in human lymphocyte cultures
Fontana et al. Can astrocytes and C6 glial cells substitute for macrophages by their production of IL-1?
Lachman Monoclonal antibody to human IL 1 and hybrid cell lines secreting IL 1
Fletcher NIH, Bethesda

Legal Events

Date Code Title Description
PC1A Transfer granted